DARE

Dare Bioscience, Inc. (ticker: DARE) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of DARE's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. DARE reported $152K in revenue and -$3.00M for the period ending 2026-03-31, with operating cash flow of -$5.52M. Cash and equivalents stood at $18.52M (up 79.3% year-over-year). Total assets of $27.83M exceed total liabilities of $27.09M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.